Medtronic's heart device unit may ease earnings pressure from Omicron – Reuters

Medtronic's heart device unit may ease earnings pressure from Omicron – Reuters

FILE PHOTO – An empty bed is pictured at the Children’s Hospital of Georgia in Augusta, Georgia, U.S., January 14, 2022. REUTERS/Hannah Beier
Feb 18 (Reuters) – Steady sales of pacemakers and heart stents may have likely helped Medtronic Plc (MDT.N) offset weak demand for its other medical devices, in a quarter that saw an Omicron-led surge in COVID-19 cases and staffing crisis at most U.S. hospitals.
Overwhelmed by soaring infections and shortages of nurses and other healthcare workers, hospitals had to put off non-critical surgical procedures, denting demand for knee and spine implants made by companies such as Medtronic and Zimmer Biomet .
"Medtronic has areas you know, for example, in cardiac surgery … those procedures are not seeing delays, but in areas where we can defer like spine, spinal cord stimulation, that’s where they’re going to see more of an impact," said BTIG analyst Ryan Zimmerman.
"So it’s less severe for Medtronic, but it’s certainly generally going to lower their fiscal third-quarter 2022 numbers."
Click here for an interactive graphic: https://tmsnrt.rs/3sSVnLw
THE CONTEXT
** During its second quarter ended Oct. 29, the hit to sales of some of Medtronic’s products such as its spinal devices, which rely on elective procedures, was offset by the strength in its business that sells critical implants including pacemakers and other heart devices.
** Smaller rivals Zimmer Biomet and Edwards Lifesciences (EW.N) have said the pressure on elective procedures has continued early into the year.
Click here for an interactive graphic: https://tmsnrt.rs/3LL3HFO
THE FUNDAMENTALS
** Medtronic, which reports results on Feb. 22, is expected to post third-quarter revenue of $7.88 billion, according to the mean estimate from 12 analysts, based on Refinitiv data
** Medtronic reported second-quarter revenue of $7.85 billion
WALL STREET SENTIMENT
** The current average rating on Medtronic shares is "buy", with six analysts rating it "strong buy", 15 "buy" and nine "hold"
** Wall Street’s median 12-month price target is $128
** The company’s shares have fallen about 1.69% so far this year
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source


Leave a Reply

Your email address will not be published.